AI-Powered Ankylosing Spondylitis Research

Ankylosing spondylitis is an inflammatory arthritis primarily affecting the spine and sacroiliac joints. AI agents research IL-17 blockade, new bone formation prevention, and microbiome-joint axis modulation.

Standard of Care

NSAIDs (first-line), TNF inhibitors (adalimumab, etanercept, golimumab), IL-17 inhibitors (secukinumab, ixekizumab), JAK inhibitors (tofacitinib, upadacitinib), physical therapy/exercise.

Prevalence

~2.7 million Americans with axSpA. HLA-B27 positive in ~90%. Onset typically age 17–45.

Key Biomarkers

• HLA-B27
• MRI sacroiliitis (bone marrow edema)
• CRP/ESR
• BASDAI score
• Radiographic progression (mSASSS)

Emerging Research

Bimekizumab (dual IL-17A/F inhibitor) for AS. Understanding the paradox: inflammation drives new bone formation, but anti-inflammatory treatment may not prevent ankylosis. Wnt/BMP pathway inhibitors to prevent spinal fusion. Gut-joint axis — subclinical gut inflammation in ~70% of AS patients. Exercise programs specifically designed for AS.

Frequently Asked Questions

Why does AS cause spinal fusion?

Chronic inflammation at entheses (tendon/bone junctions) triggers a repair response involving new bone formation. Over time, bony bridges (syndesmophytes) connect vertebrae, leading to spinal fusion (bamboo spine). Paradoxically, anti-inflammatory biologics may slow but don't fully prevent new bone formation — additional pathways (Wnt, BMP) drive this process.

How important is exercise for AS?

Exercise is as important as medication in AS management. Regular stretching, strengthening, and aerobic exercise maintain spinal mobility, reduce pain, and improve function. Swimming, yoga, and Pilates are particularly beneficial. The 5-minute daily AS exercise routine is supported by ASAS (international AS society) guidelines.